VSI Overview

Every two minutes a woman dies in pregnancy or childbirth around the globe. VSI is working to change this by connecting women with life-saving medicines and services. This document provides an overview of VSI's approach to access as well as key accomplishments improving product availability in developing countries.

Registration Map

Global registration status of misoprostol for obstetric uses

Misoprostol Use in Postabortion Care: A Service Delivery Toolkit

This toolkit is designed to help district or national-level clinicians, facility managers or program managers initiate the use of misoprostol as a medical treatment for incomplete abortion or integrate misoprostol into existing postabortion care services.

Click here to download the Toolkit in French. / La version française se trouve ici.

Click here to download the Toolkit in Portuguese. / Descarregar a versão em português aqui.

Contraceptive Pocket Guide

A pocket reference for clinicians, this Contraceptive Pocket Guide details the contraceptive methods that can be used after postabortion care services both with misoprostol and manual vacuum aspiration (MVA).

Misoprostol Information, Education and Communication

Examples from the Field

A guide to assist program planners on developing information, education and communication (IEC) campaigns as part of a misoprostol program. The focus of the content and messaging is on misoprostol for the prevention and treatment of postpartum hemorrhage (PPH) in Africa.

VSI Strategic Framework 2010-2013

A four year plan to bring effective & affordable health technologies to women in the developing world

Approved by the Board of Directors in July 2010, the enclosed resource sets outs VSI's vision and four year strategy to achieve its mission.

Misoprostol

Strategies, Successes, & Challenges

Presented in 2010 at the "Expanding Access to Essential Maternal Health Commodities" conference in Washington DC, this powerpoint presentation highlights regulatory accomplishments to date and next steps for increasing access to misoprostol for women's health.